Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy

dc.contributor.authorKidwell, Kelley M.
dc.contributor.authorHarte, Steven E.
dc.contributor.authorHayes, Daniel F.
dc.contributor.authorStorniolo, Anna Maria
dc.contributor.authorCarpenter, Janet
dc.contributor.authorFlockhart, David A.
dc.contributor.authorStearns, Vered
dc.contributor.authorClauw, Daniel J.
dc.contributor.authorWilliams, David A.
dc.contributor.authorHenry, N. Lynn
dc.contributor.departmentDepartment of Medicine, IU School of Medicineen_US
dc.date.accessioned2015-11-13T19:45:11Z
dc.date.available2015-11-13T19:45:11Z
dc.date.issued2014-08-15
dc.description.abstractBACKGROUND: Aromatase inhibitor (AI) therapy results in substantial survival benefits for patients with hormone receptor-positive breast cancer. The rates of poor adherence and discontinuation of AI therapy are high, primarily because of treatment-related toxicities like musculoskeletal pain. Although pain-related symptoms may worsen during AI therapy, the authors hypothesized that nonpersistence with AI therapy was associated with symptoms that were present before treatment initiation. METHODS: Postmenopausal women initiating AI therapy who were enrolled in a prospective clinical trial completed questionnaires at baseline to assess sleep, fatigue, mood, and pain. Reasons for treatment discontinuation during the first year of treatment were recorded. Associations between baseline patient-reported symptoms and treatment discontinuation because of toxicity were identified using logistic regression. RESULTS: Four hundred forty-nine patients were evaluable. The odds of treatment discontinuation were higher in patients who reported a greater number of symptoms before AI initiation. Baseline poor sleep quality was associated with early treatment discontinuation, with an odds ratio (OR) of 1.91 (95% confidence interval [CI], 1.26-2.89; P = .002). Baseline presence of tired feeling and forgetfulness had similar ORs for discontinuation (tired feeling: OR, 1.76; 95% CI, 1.15-2.67; P = .009; forgetfulness: OR, 1.66; 95% CI, 1.11-2.48; P = .015). An increasing total number of baseline symptoms was associated with an increased likelihood of treatment discontinuation, with an OR of 1.89 (95% CI, 1.20-2.96; P = .006) for 3 to 5 symptoms versus 0 to 2 symptoms. CONCLUSIONS: Symptom clusters in breast cancer survivors that are present before the initiation of adjuvant AI therapy may have a negative impact on a patient's persistence with therapy. Interventions to manage these symptoms may improve breast cancer outcomes and quality of life.en_US
dc.eprint.versionAuthor's manuscripten_US
dc.identifier.citationKidwell, K. M., Harte, S. E., Hayes, D. F., Storniolo, A. M., Carpenter, J., Flockhart, D. A., … Henry, N. L. (2014). Patient-Reported Symptoms and Discontinuation of Adjuvant Aromatase Inhibitor Therapy. Cancer, 120(16), 2403–2411. http://doi.org/10.1002/cncr.28756en_US
dc.identifier.urihttps://hdl.handle.net/1805/7449
dc.language.isoen_USen_US
dc.publisherWileyen_US
dc.relation.isversionof10.1002/cncr.28756en_US
dc.relation.journalCanceren_US
dc.rightsIUPUI Open Access Policyen_US
dc.sourcePMCen_US
dc.subjectAromatase inhibitoren_US
dc.subjectBreast canceren_US
dc.subjectNonpersistenceen_US
dc.subjectPatient-reported outcomesen_US
dc.subjectSymptomsen_US
dc.titlePatient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapyen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
nihms599338.pdf
Size:
201.17 KB
Format:
Adobe Portable Document Format
Description:
Main Article
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.88 KB
Format:
Item-specific license agreed upon to submission
Description: